Drug Development

Mast’s sickle cell drug flunks PhIII, eclipsing shares

Turn out the lights, the party is over at Mast Therapeutics. The San Diego-based biotech, a penny stock microcap, announced after the market closed on Tuesday that its Phase III study of an experimental drug for sickle cell disease flopped, unable to differentiate itself from a sugar pill.

Mast CEO Brian M. Culley

Mast CEO Brian M. Culley

Mast’s already battered shares $MSTX dropped 76%, to 13 cents a share, on the news.

There’s some analysis of the data left to do on vepoloxamer, but the company say’s it is ready to wash its hands of the drug. Then it can examine its remaining options.

“(B)ased on the data we’ve seen to date, we expect we will terminate all clinical development of vepoloxamer,” said CEO Brian M. Culley. “Consequently, while we evaluate our options, we intend to significantly and immediately reduce our operating expenses and continue our efforts with AIR001, our lead asset in heart failure with preserved ejection fraction, which currently is the subject of a 100-patient phase 2 study expected to complete enrollment by the end of 2017.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->